XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 26.52

-22.9%

Dec 11 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bluegreen who wrote (14633)	9/16/2000 8:27:21 PM
From: Robert K.	Read Replies (1) of 17367

I think Bluegreen has hit the mark(or ageed with what I previously said). The whole issue is the bpi/meningo trial almost COULDNT show benefit as designed. Yet, there was a seeming benefit in mortality, amputations and POCP(sp). Some were statistical, some were not. This is IN SPITE of the fact that the trial was underpowered. The fact is the drug is safe and the drug is showing benefit and the FDA is denying access. IMO there is NO REASON the drug should not be conditionally approved and true benefit decided BY THE FDA after the fact. If it doesnt work, then pull it OFF the market, but dont let more kids die to prove a point. If the FDA would rather see more kids die to prove benefit then its a sorry day indeed. Seems Cacaito supports the concept. NO...let me repeat NO, i am not saying Cacaito wants more kids to die, only that more kids dying would be the NET result of his path.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next